GET DAILY SIGNALSOption Care Health (OPCH) Q3 Earnings Preview Amid the Pending Take-Private Deal
Key Takeaways
- Option Care Health is scheduled to report its third quarter 2026 results, for the period ended September 30, 2026, on November 4, 2026, before the market opens.
- Consensus estimates point to earnings of approximately $0.44 per share, according to data tracked by EarningsWhispers.
- The report arrives under unusual circumstances: the company is being acquired by Clayton Dubilier & Rice (CD&R) and McKesson for $32.05 per share and has withdrawn its previously disclosed financial guidance.
- Management will not host a conference call for the third quarter, removing a key source of forward-looking commentary for investors.
- Investors will focus on revenue growth, adjusted EBITDA, and margin trends against the backdrop of the pending $5.8 billion take-private transaction.
- For reference, second quarter 2026 revenue was $1.44 billion, up 1.8% year over year, with diluted earnings per share of $0.35.
Earnings Context and Why It Matters
This quarter is defined less by the income statement than by the transaction reshaping the company. On October 6, 2026, Option Care Health announced a definitive agreement under which CD&R and McKesson will acquire the home and alternate site infusion services provider for $32.05 per share, a roughly 37% premium to its prior close, valuing the company at about $5.8 billion. Because the deal is pending, the company has withdrawn its guidance and will not hold a quarterly call. That makes the reported figures a snapshot of the business ahead of an expected first-half 2027 closing, while investors weigh operating trends against the agreed take-private price. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Consensus estimates for the third quarter of 2026 call for earnings of approximately $0.44 per share, according to EarningsWhispers. This compares with diluted earnings per share of $0.35 reported in the second quarter of 2026 and $0.32 in the third quarter of 2025. Analysts will closely track net revenue, which reached $1.44 billion in the second quarter of 2026, reflecting a 1.8% year-over-year increase, as well as adjusted EBITDA and gross margin. In the absence of a conference call and formal guidance, investors will rely on these headline metrics to gauge the company's underlying momentum heading into the pending acquisition. From what I see, these numbers provide the clearest available window into operations right now.
Market Reaction and Investor Sentiment
Sentiment surrounding OPCH is now dominated by the acquisition rather than quarterly fundamentals. Shares jumped roughly 33% in premarket trading after the deal announcement and have since traded near the $32.05 offer price, limiting the usual pre-earnings volatility driven by estimates. Because the transaction sets a known exit value, the third quarter report is unlikely to produce the sharp, estimate-driven swings typical of a standalone company. Instead, investors will watch for any signs of operational deterioration or unexpected weakness that could complicate closing, though the primary risks remain regulatory approvals, stockholder approval, and the deal's anticipated first-half 2027 completion. I'm watching this closely as the focus shifts away from typical earnings beats or misses.
Forward Outlook and Key Factors to Monitor
With formal guidance withdrawn, the forward view centers on the transaction's path to completion rather than multi-quarter operating projections. The deal is expected to close in the first half of calendar year 2027, subject to stockholder approval and regulatory clearances, including antitrust review under the Hart-Scott-Rodino Act and various healthcare filings.
Investors should monitor any updates on the merger timeline and conditions, as delays or required remedies could influence the outcome. On the operational side, watch for trends in revenue growth, gross margin, and adjusted EBITDA in the third quarter release, which will serve as the clearest signal of business health during the pendency period.
Cost and demand dynamics in home and alternate site infusion remain relevant, given the broader shift toward lower-cost, community-based care settings that underpinned the deal's strategic logic. Until the transaction closes, the offer price will continue to anchor the stock, with any deviation reflecting perceived risks to deal completion rather than ordinary earnings performance.
Exploring Tickeron’s AI Tools for This Analysis
In preparing for this earnings release, I turned to Tickeron’s AI Daily Buy/Sell Signals to cross-check momentum indicators and see how OPCH stacks up against peers in the healthcare services space. The platform’s pattern recognition helped highlight how acquisition-related trading has overshadowed typical technical signals lately, which aligns with the muted volatility I expect around the report.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OPCH in upward trend: 10-day moving average crossed above 50-day moving average on October 07, 2026
The 10-day moving average for OPCH crossed bullishly above the 50-day moving average on October 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on OPCH as a result. In 56 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
OPCH moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +0.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPCH advanced for three days, in 174 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
The Aroon Indicator entered an Uptrend today. In 136 of 217 cases where OPCH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 74 cases where OPCH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for OPCH turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 32 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPCH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
OPCH broke above its upper Bollinger Band on October 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OPCH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPCH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.787) is normal, around the industry mean (204.282). P/E Ratio (23.947) is within average values for comparable stocks, (19.375). Projected Growth (PEG Ratio) (1.101) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.096) among similar stocks. P/S Ratio (0.682) is also within normal values, averaging (2.688).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of home and alternate site infusion services.
Industry HospitalNursingManagement
Advertisement